Withdrawal of 'Xigris' from the market: Old and new lessons

Journal of Epidemiology and Community Health

Volumn 66, Issue 7, 2012, Pages 571-572

  Poole, Daniele ^a   Bertolini, Guido ^b   Garattini, Silvio ^c  

^a SAN MARTINO HOSPITAL   (Italy)

^b Centro di Ricerche Cliniche Per le Malattie Rare 'Aldo e Cele Daccò'   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; PROTEIN C; RECOMBINANT PROTEIN;

DRUG RECALL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; UNITED STATES;

ANTI-INFECTIVE AGENTS; DRUG RECALLS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864020814     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2012-200977     Document Type: Editorial

References (14)

1. US Food and Drug Administration. Center for Drug Evaluation and Research. Anti-Infective drug Advisory Committee. Meeting on Xigris approval transcriptions, 2001. http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Anti-Infective (accessed Feb 2012).
2. Poole D, Bertolini G, Garattini S. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis 2009;9:67-72.
3. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004;32:2199-206.
4. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41.
5. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-55.
6. Bertolini G, Rossi C, Anghileri A, et al. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 2007;33:426-34.
7. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
8. EMA. Xigris (Drotrecogin Alfa (Activated)) to be Withdrawn Due to Lack of Efficacy. http://www.ema.europa.eu/ema/index.jsp?curl1/4pages/news_and_events/news/2011/2010/news_detail_001373.jsp&mid1/4WC001370b001301ac058004d001375c001371&murl1/4menus/news_and_events/news_and_events.jsp (accessed Nov 2011).
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
10. US Food and Drug Administration. Drotrecogin Alpha (Activated), Xigris. BLA # 125029/0. FDA Clinical Review. 2001. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/UCM113438.pdf (accessed Feb 2012).
11. Malacarne P, Langer M, Nascimben E, et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit Care Med 2008;36:1105-13.
12. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-21.
13. Annane D, Aegerter P, Jars-Guincestre MC, et al. Current epidemiology of septic shock: the CUB-rea network. Am J Respir Crit Care Med 2003;168:165-72.
14. Wagner W, McGarity T. Regulatory reinforcement of journal conflict of interest disclosures: how could disclosure of interests work better in medicine, epidemiology and public health? J Epidemiol Community Health 2009;63:606-7.